We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Groundbreaking Blood Test Offers Early Pancreatic Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 Mar 2024
Print article
Image: The simple blood test can measure changes in cellular metabolism arising from pancreatic cancer (Photo courtesy of Metabolomycs)
Image: The simple blood test can measure changes in cellular metabolism arising from pancreatic cancer (Photo courtesy of Metabolomycs)

Pancreatic cancer ranks as the third leading cause of cancer-related deaths, primarily due to its late detection. Early discovery of the disease, while it's still treatable, could significantly impact survival rates. For more than a century, scientists have sought to link cancer with cellular energy production and metabolism. The advent of quantitative mass spectrometry has enabled the testing of many such theories. Now, for the first time, researchers have utilized targeted mass spectrometry to demonstrate that pancreatic cancer stems from changes in cellular metabolism that are detectable using a simple blood test. This method could lead to more precise and earlier diagnoses of pancreatic cancer than currently possible with tumor markers or imaging techniques, potentially paving the way for more timely and appropriate therapeutic interventions.

In contrast to genomic approaches that measure DNA for early detection and often struggle with false positives and negatives, mass spectrometry can measure extremely low concentrations of biochemicals in plasma with remarkable accuracy. Scientists at Metabolomycs (Long Beach, CA, USA) have found that these metabolic signatures in the blood can predict survival rates in patients battling this aggressive cancer. This discovery marks a new direction in pancreatic cancer research, moving beyond genomics and DNA analysis to define the disease as a metabolic disorder.

According to the researchers, variations in amino acids, blood sugars, and lipids define cancer as a state of metabolic stress. Metabolomics, a novel scientific field, employs sensitive tools like mass spectrometry to quantify metabolic byproducts in blood and other bodily fluids. Although mass spectrometry has broad applications, the emergence of targeted mass spectrometry has facilitated its direct clinical use. For the first time, researchers can accurately measure blood levels of metabolic byproducts in real-time. This enabled the researchers to discover highly discriminating ratios that pitted amino acids, the building blocks of proteins, against lipids including triglycerides and sugars like glucose. These findings provide a unique "cancer signature" that differentiates individuals with pancreatic cancer from healthy subjects and can also distinguish pancreatic cancer from other cancer types, such as breast and ovarian cancer.

"What we find is that pancreatic cancers establish a new set of rules for making and using energy that propel these malignant tumors to succeed, all at the expense of the cancer patient's wellbeing," said Dr. Robert Nagourney. "Our findings show that these metabolic tests have the potential to identify pancreatic cancers at the earliest stages when it is still possible to cure the patient. They can also be used to define risk groups that help predict a patient's likelihood of survival."

Related Links:
Metabolomycs

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.